SCARNA20

Across TCGA pan-cancer cohorts, SCARNA20 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SCARNA20’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SCARNA20 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SCARNA20 is over-expressed in tumor, although a few such as LIHC show the opposite, repressed pattern.

HNSC, ESCA, and KIRC are the cancer types where SCARNA20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SCARNA20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	+0.403	<.001	8	view →
ESCA	All	All	+1.001	.003	3	view →
KIRC	Male	III,IV	+0.245	.008	3	view →
LIHC	Male	II,III,IV	−0.194	.013	3	view →
BLCA	All	All	+0.464	.047	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SCARNA20–HNSC

Open the HNSC breakdown →